A story this week in the New York Times discusses the need for an alternative to pig-derived pancreatic enzyme supplements for cystic fibrosis patients. It highlights the Foundation's collaboration with Altus Pharmaceuticals to develop a synthetic, non-animal derived product.

Preston W. Campbell, III, M.D., executive vice president for medical affairs of the Cystic Fibrosis Foundation, says in the article that if a problem developed in the pig population and resulted in a recall of enzymes, it could be a serious health threat for  people with CF. That's why the Foundation is proactively pursuing a synthetic alternative, he said.

Read the full story.